Navigation Links
Omeros to Present at the Cowen and Company 32nd Annual Health Care Conference
Date:3/1/2012

SEATTLE, March 1, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Cowen and Company 32nd Annual Health Care Conference taking place in Boston, Massachusetts next week.  The presentation is scheduled for Wednesday, March 7, 2012 at 11:20 a.m. Eastern Time.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.  

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cng4gn/refurbished ) has announced the ... Global Forecasts to 2019" report to their offering. ... estimated to grow expected to reach $9.37 billion by ... 2019. Factors such as growing ... increasing privatization in the healthcare sector, and rising adoption ...
(Date:7/28/2015)... 28, 2015  PD-Rx Pharmaceuticals, Inc., a publicly ... has partnered with Dobson Technologies, a fully-integrated outsourced ... (IaaS) product. PD-Rx is an Application ... United States.  Using Dobson Technologies, IaaS solution will ... continuity, ensure regulatory compliance, and reduce operating expenses.  ...
(Date:7/28/2015)... , July 28, 2015  For many medical ... researchers, physicians and other inventors can be a constant ... is difficult, and successes are rare. A ... to change that. Medical Device Investments (MDI) ... from universities, hospitals and physicians. MDI develops, manufactures and ...
Breaking Medicine Technology:Refurbished Medical Equipment Market 2015 - Global Forecasts to 2019 2PD-Rx Partners With Dobson Technologies 2Medical Device Investments To Become Center Of Excellence For The Commercialization Of Innovative Medical Technologies 2
... and TARRYTOWN, N.Y., Nov. 10, 2011 Sanofi ... and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ... Phase 2 study program in which patients with ... REGN727/SAR236553. REGN727/SAR236553 is a novel, high-affinity, ...
... NASHVILLE, Tenn., Nov. 9, 2011 Revenue ... Non-GAAP Adjusted EBITDA of $76.7 million, increased 15.3% over third ... of healthcare revenue and payment cycle management and clinical information ... ended September 30, 2011, as summarized below: (In millions, except ...
Cached Medicine Technology:Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia 2Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia 3Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia 4Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia 5Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia 6Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia 7Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia 8Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia 9Emdeon Reports Third Quarter 2011 Results 2Emdeon Reports Third Quarter 2011 Results 3Emdeon Reports Third Quarter 2011 Results 4Emdeon Reports Third Quarter 2011 Results 5Emdeon Reports Third Quarter 2011 Results 6Emdeon Reports Third Quarter 2011 Results 7Emdeon Reports Third Quarter 2011 Results 8Emdeon Reports Third Quarter 2011 Results 9Emdeon Reports Third Quarter 2011 Results 10Emdeon Reports Third Quarter 2011 Results 11Emdeon Reports Third Quarter 2011 Results 12Emdeon Reports Third Quarter 2011 Results 13
(Date:7/28/2015)... ... July 28, 2015 , ... The Triumph Modular, ... practices, consumer education, resource library, floor plans, educational blog and wide use of ... offers regular posts with valuable links to useful reports by industry experts. Comments ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... announces the Lost and Found, a breakthrough technological invention. It is a ... for the consumer electronic industry reached a record high of $211.3 billion in ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Morristown Medical Center, ... Jersey, and one of the first five hospitals in the nation, to implant the ... patients on July 23, and all are in good condition. , The CoreValve® Evolut® ...
(Date:7/28/2015)... ... July 28, 2015 , ... DuPont leaders today ... Ethiopia to learn more about the impact of U.S. collaborations with local partners ... on accelerating agricultural development as an engine of broad-based economic growth in the ...
(Date:7/28/2015)... ... 2015 , ... Women in Technology (WIT), the premier organization contributing to the ... has selected Lisa Dezzutti, CEO and president at Market Connections, Inc. as the organization’s ... this organization that empowers women to thrive and excel in the technology field. In ...
Breaking Medicine News(10 mins):Health News:Triumph Modular Launches Refreshed Modular Building Industry Website 2Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 2Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 3Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 4Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 5Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 2Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 4Health News:Lisa Dezzutti Named President of Women in Technology (WIT) Board of Directors 2
... , VANCOUVER, June 10 /PRNewswire-FirstCall/ - Response Biomedical Corporation ... Livleen Kaler has been appointed Vice President Finance & ... years of financial management experience in several industries. , ... the Board is pleased to recognize Livleen for her ...
... Trust Inc. (NYSE: CRE ) ("Care" or the ... dividend of $0.17 per share of common stock for the first ... to common shareholders of record on June 23, 2009. , ... Trust Inc. is a real estate investment and finance company investing ...
... One of Bucks County,s largest employers will create more than ... the help of a new state investment in an ongoing ... an $11.1 million grant, on behalf of the Doylestown Hospital, ... , , The funds will be used ...
... statement from the American Chemistry Council regarding papers ... including: "Bisphenol-A Exposure In Utero Leads to Epigenetic ... "Low-Dose Bisphenol A Promotes Arrhythmogenesis in the Female ... Belcher, PhD; and "Oral Exposure of Female Rhesus ...
... find similar results , WEDNESDAY, June 10 (HealthDay News) ... drugs after radiation therapy do better when the drug treatment ... six-month regimen, a European study has found. , The results ... in May, said Dr. Eric M. Horwitz, acting chairman of ...
... Metoclopramide, a drug approved in the U.S. for nausea, ... according to a large cohort study published in the June ... Medicine , "The Safety of Metoclopramide Use in the First ... June 11, 2009). According to the pediatrician and clinical ...
Cached Medicine News:Health News:Response Biomedical Corporation Announces Appointment of Vice President Finance & Administration and Chief Financial Officer 2Health News:Response Biomedical Corporation Announces Appointment of Vice President Finance & Administration and Chief Financial Officer 3Health News:Response Biomedical Corporation Announces Appointment of Vice President Finance & Administration and Chief Financial Officer 4Health News:Care Investment Trust Inc. Announces Quarterly Dividend 2Health News:State to Invest $11.1 Million in Expansion of Doylestown Hospital 2Health News:Press Releases on BPA Studies By-Pass Scientific Process 2Health News:Longer Hormone Treatment May Improve Prostate Cancer Outlook 2Health News:Longer Hormone Treatment May Improve Prostate Cancer Outlook 3Health News:Off-label morning sickness drug deemed safe for fetuses -- Ben-Gurion U. researchers 2
... of a Matching Card, three HRR symbol cards ... a child for subsequent HRR 4th Edition color ... test. For the youngest patients, the parents can ... the concept of matching and become familiar with ...
Magnetic Farnsworth D15 kit. Magnets move the color disks. Protects disks from fingerprints. Keeps all the disks in one place. Clear glass insures accurate color perception. Makes color testing fun....
... test from Richmond Products includes the four demonstration ... diagnostic series for a total of 24 plates. ... for easy and clean page selection. The test ... and a laminated copy of the score sheet. ...
Ishihara 14 plate color vision testing set. Suitable for screening purposes....
Medicine Products: